Table 3 Prothrombin complex concentrate brand and first dose
Study, Year | PCC3 brand | PCC4 brand * | Dose PCC3 (u/kg) | Dose PCC4 (u/kg) | Dose PCC3 (units) | Dose PCC4 (units) |
|---|---|---|---|---|---|---|
Al-Majzoub et al., 2016 [20] | Profilnine® SD | KCentra® | 25.5 (4.3) | 27.9 (6.9) | NR | NR |
DeAngelo et al., 2018 [22] | Profilnine® SD | KCentra® | 25 [23–27] | 23 [20–27] | 2080 [1940–2500]* | 1620 [1301–2213]* |
Fischer et al., 2018 [24] | Profilnine® SD | KCentra® | 26 [20–41] | 25 [23–29] | 2000 [1500–3248] | 2088 [1665–2500] |
Holt et al., 2018 [25] | NR | NR | 24.6 (9.3) | 36.3 (12.8) | NR | NR |
Jones et al., 2016 [27] | Bebulin® VH | KCentra® | 30.6 [28.2–32.3] | 26.3 [24.7–34.3] | 2454 [2228–3045] | 2500 [2000–2852] |
Kuroski et al., 2017 [28] | Bebulin® VH | KCentra® | 28.9 (22.5–40.1), median (range) | 25 (12–50) | NR | NR |
Mangram et al., 2016 [30] | Bebulin® VH | KCentra® | 29 (9) | 26 (6) | NR | NR |
Margraf et al., 2020 [31] | Profilnine® SD | KCentra® | 21.5 [20.4–25.9] | 29.3 [25.9–37.3] | 2000 [1530–2500] | 2595 [1880–3307] |
Mohan et al., 2018 [32] | Bebulin® VH | KCentra® | 40.99 (18), median (40.04) | 32.22 (11.07), median (27.35) | 3073 (1654) | 2472 (930) |
Voils et al., 2015 [33] | Profilnine® SD | KCentra® | 28 [25–31] | 27 [24–31] | 2250 [1980–2970] | 2250 [1788–2940] |
Cang et al., 2014 [21] | NR | NR | NR | NR | NR | NR |
Di Napoli et al., 2014 [23] | NR | NR | NR | NR | NR | NR |
Kotsianas et al., 2015 [26] | NR | NR | NR | NR | NR | NR |
Peck et al., 2016 [29] | NR | NR | NR | NR | NR | NR |
Wagner et al., 2019 [34] | NR | NR | NR | NR | NR | NR |
|  |  | * All US studies are assumed to have used Kcentra® |  |  |  | *First dose |